Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis

被引:7
|
作者
Mori, Kazuma [1 ,8 ]
Akiyama, Yukinori [2 ]
Tanaka, Marenao [1 ]
Sato, Tatsuya [1 ,3 ]
Endo, Keisuke [1 ]
Hosaka, Itaru [4 ]
Hanawa, Nagisa [5 ]
Sakamoto, Naoya [6 ,7 ]
Furuhashi, Masato [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Cardiovasc Renal & Metab Med, S-1,W-16,Chuo Ku, Sapporo 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Japan
[3] Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Japan
[4] Sapporo Med Univ, Sch Med, Dept Cardiovasc Surg, Sapporo, Japan
[5] Keijinkai Maruyama Clin, Dept Hlth Checkup & Promot, Sapporo, Japan
[6] Hokkaido Univ, Fac Med, Dept Gastroenterol & Hepatol, Sapporo, Japan
[7] Grad Sch Med, Sapporo, Japan
[8] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Japan
基金
日本学术振兴会;
关键词
clustering; machine learning; metabolic dysfunction-associated fatty liver disease (MAFLD); metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); CLINICAL-PRACTICE GUIDELINES; DELPHI CONSENSUS STATEMENT; ALCOHOL-CONSUMPTION; HEPATITIS-C; INDEX; RISK; INDIVIDUALS; PREVALENCE; MECHANISMS; FACTORIAL;
D O I
10.1111/jgh.16552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimNew nomenclature of steatotic liver disease (SLD) including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) has recently been proposed. We investigated clustering analyses to decipher the complex landscape of SLD pathologies including the former nomenclature of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsJapanese individuals who received annual health checkups including abdominal ultrasonography (n = 15 788, men/women: 10 250/5538, mean age: 49 years) were recruited.ResultsThe numbers of individuals with SLD, MASLD, MetALD, ALD, NAFLD, and MAFLD were 5603 (35.5%), 4227 (26.8%), 795 (5.0%), 324 (2.1%), 3982 (25.8%), and 4946 (31.3%), respectively. Clustering analyses using t-distributed stochastic neighbor embedding and K-means to visually represent interconnections in SLDs uncovered five cluster formations. MASLD and NAFLD mainly shared three clusters including (i) low alcohol intake with relatively low-grade obesity; (ii) obesity with dyslipidemia; and (iii) dysfunction of glucose metabolism. Both MetALD and ALD displayed one distinct cluster intertwined with alcohol consumption. MAFLD widely shared all of the five clusters. In machine learning-based analyses using algorithms of random forest and extreme gradient boosting and receiver operating characteristic curve analyses, fatty liver index (FLI), calculated by body mass index, waist circumference, and levels of gamma-glutamyl transferase and triglycerides, was selected as a useful feature for SLDs.ConclusionsThe new nomenclature of SLDs is useful for obtaining a better understanding of liver pathologies and for providing valuable insights into predictive factors and the dynamic interplay of diseases. FLI may be a noninvasive predictive marker for detection of SLDs. 1 image
引用
收藏
页码:1382 / 1393
页数:12
相关论文
共 50 条
  • [31] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [32] Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients
    Babu, Ambrin Farizah
    Palomurto, Saana
    Karja, Vesa
    Kakela, Pirjo
    Lehtonen, Marko
    Hanhineva, Kati
    Pihlajamaki, Jussi
    Mannisto, Ville
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (12) : 2103 - 2110
  • [33] Association of antinuclear antibody positivity with liver disease severity in pediatric metabolic dysfunction-associated steatotic liver disease
    Kim, Hyun Jin
    Kim, Ju Young
    Lee, Yoo Min
    Hong, Yong Hee
    Kang, Ben
    Choe, Byung-Ho
    Yi, Dae Yong
    Lee, Eun Hye
    Kim, Soon Chul
    Choi, You Jin
    Jang, Hyo-Jeong
    Choi, So Yoon
    FRONTIERS IN PEDIATRICS, 2025, 13
  • [34] The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
    Paklar, Natasa
    Mijic, Maja
    Filipec-Kanizaj, Tajana
    BIOMEDICINES, 2023, 11 (11)
  • [35] Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
    Salazar, Melchor Alpizar
    Reyes, Samantha Estefania Olguin
    Estevez, Andrea Medina
    Lobos, Julieta Alejandra Saturno
    Castillo, Jesus Manuel De Aldecoa
    Aguas, Juan Carlos Carrera
    Monreal, Samary Alaniz
    Rodriguez, Jose Antonio Navarro
    Sanchez, Dulce Maria Fernanda Alpizar
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [36] Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
    Moon, Sang Yi
    Son, Minkook
    Cho, Jung-Hwan
    Kim, Hye In
    Han, Ji Min
    Bae, Ji Cheol
    Suh, Sunghwan
    THYROID, 2025, 35 (01) : 79 - 86
  • [37] The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Kashihara, Takanori
    Shinomiya, Ryo
    Miyake, Takanori
    Kawaguchi, Tomoyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Kida, Yoshifumi
    Okada, Yasuyuki
    Tomonari, Tetsu
    Kawano, Yutaka
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1587 - 1598
  • [38] From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
    Bruno Basil
    Blessing K. Myke-Mbata
    Onyinye E. Eze
    Augustine U. Akubue
    Clinical Diabetes and Endocrinology, 10 (1):
  • [39] Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    El-Kassas, Mohamed
    Awad, Abeer
    Elbadry, Mohamed
    Arab, Juan Pablo
    SEMINARS IN LIVER DISEASE, 2024, 44 (01) : 54 - 68
  • [40] Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review
    Joo, Sae Kyung
    Kim, Won
    EWHA MEDICAL JOURNAL, 2024, 47 (02):